Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Article
CAS
Google Scholar
Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced hepatocellular carcinoma: current standard and the future. Clin Liver Dis (Hoboken). 2019;13:13–9.
Article
Google Scholar
Mehta N. Hepatocellular carcinoma-How to determine therapeutic options. Hepatol Commun. 2020;4:342–54.
Article
Google Scholar
Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22:7289–300.
Article
Google Scholar
Liu YC, Mao YZ, Wang JC, Wang J, Lao XM, Chen MS, et al. Hepatocellular carcinoma with en bloc diaphragmatic resection: a single-center experience over 14 years. Int J Surg. 2018;53:93–7.
Article
Google Scholar
Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study. Cancer Manag Res. 2019;11:2759–68.
Article
Google Scholar
Liao X, Zhang D. The 8th Edition American Joint Committee on cancer staging for hepato-pancreato-biliary cancer: a review and update. Arch Pathol Lab Med. 2020. https://doi.org/10.5858/arpa.2020-0032-RA.
Article
PubMed
Google Scholar
Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7:2641–53.
Article
CAS
Google Scholar
Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, et al. New Inuyama classification; New criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112–9.
Article
Google Scholar
Sato N, Beppu T, Kinoshita K, Yuki H, Suyama K, Yuruki H, et al. Partial splenic embolization for lenvatinib therapy-associated thrombocytopenia among patients with hepatocellular carcinoma. Anticancer Res. 2019;39:6895–901.
Article
CAS
Google Scholar
Tomonari T, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports. Medicine. 2020;99:e22782.
Article
Google Scholar
Matsuki R, Kawai K, Suzuki Y, Kogure M, Nakazato T, Naruge D, et al. Pathological complete response in conversion hepatectomy induced by lenvatinib for advanced hepatocellular carcinoma. Liver Cancer. 2020;9:358–60.
Article
Google Scholar
Chen X, Zhang Y, Zhang N, Ge Y, Jia W. Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report. Onco Targets Ther. 2019;12:7355–9.
Article
Google Scholar
Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med. 2019;8:137–46.
Article
CAS
Google Scholar
Kudo M, Piscaglia F, Baron A, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.
Article
CAS
Google Scholar
Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, et al. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. Hepatol Res. 2019;49:594–9.
Article
CAS
Google Scholar
Cheng C, Nayernama A, Christopher Jones S, Casey D, Waldron PE. Wound healing complications with lenvatinib identified in a pharmacovigilance database. J Oncol Pharm Pract. 2019;25:1817–22.
Article
CAS
Google Scholar
Kuo TM, Chang KM, Cheng TI, Kao KJ. Clinical factors predicting better survival outcome for pulmonary metastasectomy of hepatocellular carcinoma. Liver Cancer. 2017;6:297–306.
Article
Google Scholar
Yamauchi M, Ono A, Ishikawa A, Kodama K, Uchikawa S, Hatooka H, et al. Tumor fibroblast growth factor receptor 4 level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol. 2020;11:e00179.
Article
Google Scholar
Wang Z, Peng Y, Hu J, Wang X, Sun H, Sun J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients. Ann Surg. 2020;271:534–41.
Article
Google Scholar